Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Bayer

Status

Conditions: Tumors Harboring NTRK Fusion

Treatments: Drug: Larotrectinib (Vitrakvi, BAY2757556)

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03025360

20366

Details and patient eligibility

About

Larotrectinib expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion, who are ineligible for an ongoing larotrectinib clinical trial or have other considerations that prevent access to larotrectinib through an existing clinical trial. Gene fusion occurs when a gene is made by joining parts of two different genes. NTRK gene fusion can lead to the development of solid tumors in a variety of tissue types. The study drug larotrectinib blocks the action of the NTRK gene fusion.

Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion who are unresponsive to current standard treatment for their condition and also are unable to participate in ongoing clinical trials.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of cancer with a NTRK1, NTRK2, or NTRK3 gene fusion
• Subjects are unable to participate in an ongoing larotrectinib clinical trial
• Medically suitable for treatment with larotrectinib

Exclusion criteria

• Currently enrolled in an ongoing clinical study of larotrectinib or another TRK inhibitor